Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Nonalcoholic fatty liver disease ups risk of death

13 Aug 2019

Nonalcoholic fatty liver disease (NAFLD) heightens the risk of all-cause death but not from cardiovascular diseases (CVD) or cancer, reports a recent meta-analysis.

Accessing the databases of PubMed and Embase, researchers retrieved 14 studies that investigated the effect of NAFLD on mortality risk. Reports that used NAFLD patients as the reference group or assessed mortality in patients undergoing bariatric surgery or liver transplantation were ineligible. The Newcastle-Ottawa scale was used to evaluate methodological quality.

A total of 24,188 deaths were reported in the cumulative sample of 498,259 participants. Pooled analysis revealed a significantly higher death risk in NAFLD patients (hazard ratio [HR], 1.34, 95 percent CI 1.17–1.54), though the evidence had substantial heterogeneity (p<0.01).

Subsequent subgroup analyses found that NAFLD was a significant mortality hazard in women (four studies; HR, 1.49, 1.15–1.93) but not in men (four studies, HR, 1.08, 0.83–1.41). In contrast, there were no meaningful effect modifications according to age, sex, NAFLD severity, the presence of fibrosis or cirrhosis, follow-up duration, comorbidities, and the method used to diagnose NAFLD.

The effect of NAFLD on death risk appeared to be robust, as excluding four studies with large sample sizes did not change the principal findings. NAFLD also exerted a similar effect on the likelihood of death from liver disease (HR, 2.53, 1.23–5.18).

On the other hand, NAFLD had no apparent effect on the risk of death from CVDs (HR, 1.13, 0.92–1.38) and cancer (HR, 1.05, 0.89–1.25).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.